What Researchers Did
Researchers conducted a cross-sectional retrospective study to examine early and late adverse outcomes in patients with severe carbon monoxide poisoning admitted to the emergency department between January 2020 and May 2022.
What They Found
Patients receiving hyperbaric oxygen therapy (HBOT) showed a significant difference in delayed neurological sequelae (DNS) compared to those receiving normobaric oxygen therapy (NBOT) (p = 0.037). Significant differences were observed in the need for intubation, in-hospital mortality, and 1-year mortality based on COHb levels, with a 1-year mortality probability significantly influenced by COHb level (odds ratio = 1.159).
What This Means for Canadian Patients
This study suggests that hyperbaric oxygen therapy may improve neurological outcomes for patients with severe carbon monoxide poisoning. These findings could help Canadian clinicians optimize treatment strategies to reduce long-term complications and mortality in affected individuals.
Canadian Relevance
This study has no direct Canadian connection.
Study Limitations
As a retrospective study, it may be subject to limitations such as selection bias or incomplete data collection.